# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and d...
Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $101...
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price ...
RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and maintains $1250 ...
This marks the first regulatory approval of Ordspono in the world for these patients. Ordspono is a bispecific antibody that ac...
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), ...